- Home
- SILO vs RDHL Comparison
SILO vs RDHL Comparison
Compare SILO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILO | RDHL |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 3.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SILO | RDHL |
|---|---|---|
| Price | $0.37 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 121.8K | 69.2K |
| Earning Date | 11-13-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $72,102.00 | ★ $9,550,000.00 |
| Revenue This Year | $1.86 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $0.36 | $1.01 |
| 52 Week High | $3.37 | $7.00 |
Technical Indicators
Market Signals| Indicator | SILO | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.47 | 47.48 |
| Support Level | $0.42 | $1.15 |
| Resistance Level | $0.46 | $1.24 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 2.73 | 33.66 |
Price Performance
Historical ComparisonAbout SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.